hat
Te òmòn nan Oxandrolone premye lage nan ane 1960 yo byen bonè anba non an komès Anavar pa GD Searle & ko. epi yo te konnen kòm pote anpil kalite terapetik. Sepandan, nan lane 1989, Searle ta sispann konpoze an; sa a te lajman akòz presyon FDA ki te sere boulon priz li yo sou mache a anabolizan esteroyid. Yon nòt enpòtan; Searle tou posede dwa yo lisans nan majorite nan Oxandrolone pwodwi sou mache mondyal la, ki ta mennen nan sa a esteroyid prèske disparèt nan moman sa a. An 1995, òmòn Oxandrolone ta repwodwi gras a Bio-Technology General CORP (BTG),
eng
The Oxandrolone hormone was first released in the early 1960’s under the trade name Anavar by G.D Searle & co. and was touted as carrying numerous therapeutic qualities. However, in 1989 Searle would discontinue the compound; this was largely due to FDA pressure that had tightened its grip on the anabolic steroid market. An important note; Searle also owned the licensing rights to the majority of Oxandrolone products on the global market, which would lead to this steroid nearly disappearing at this time. In 1995 the Oxandrolone hormone would reappear thanks to Bio-Technology General CORP (BTG),